| Bioactivity | Otlertuzumab (TRU-016) is a humanized anti-CD37 monoclonal antibody that can be used for cancer research[1]. |
| Target | CD37 |
| Invitro | Otlertuzumab (TRU-016) in combination with Rituximab (HY-P9913), Rapamycin (HY-10219), or Bendamustine (HY-13567) increases cell killing of NHL cells[2].Otlertuzumab has the ability to bind to and kill CD37+ cells[3]. |
| In Vivo | Otlertuzumab (TRU-016) in combination with Bendamustine (HY-13567) displays greater anti-tumor activity than either agent alone against a follicular lymphoma tumor model in SCID mice[2].Otlertuzumab shows significant antitumor activity in mice bearing Ramos or Daudi tumor xenografts[3]. |
| Name | Otlertuzumab |
| CAS | 1372645-37-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Byrd JC, et al. A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood. 2014 Feb 27;123(9):1302-8. [2]. Baum P R, et al. Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma. Journal of Clinical Oncology, 2009, 27(15_suppl): 8571-8571. [3]. Cerveny C G, et al. In vitro and in vivo anti-B cell lymphoma activities of TRU-016. Journal of Clinical Oncology, 2008, 26(15_suppl): 3074-3074. |